Precise Thyroxine Dosing: Clinical Requirements

Endocrinologist

Volumn 13, Issue 6, 2003, Pages 479-487

  Hennessey, James V ^a,b  

^a BROWN UNIVERSITY   (United States)

^b Hallett Center for Diabetes and Endocrinology   (United States)

Author keywords

Bioequivalence; Goal TSH values; Hypothyroidism; Therapeutic interchangeability; Thyroid cancer; Thyroxine therapy

Indexed keywords

LEVOTHYROXINE; THYROTROPIN; THYROXINE;

ACCURACY; BIOEQUIVALENCE; CANCER GROWTH; DRUG BIOAVAILABILITY; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG FORMULATION; DRUG SAFETY; DRUG SCREENING; DRUG SOLUBILITY; DRUG TARGETING; EVALUATION; HUMAN; HYPOTHYROIDISM; OUTCOMES RESEARCH; PREGNANCY; REVIEW; SENESCENCE; SYMPTOM; THYROID CANCER; THYROTROPIN BLOOD LEVEL; TITRIMETRY; TREATMENT INDICATION;

EID: 0345714865     PISSN: 10512144     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ten.0000098610.80343.56     Document Type: Review

References (47)

1. Singer P, et al. Treatment guidelines for patients with hyperthyroidism and hypothyroidism. JAMA. 1995;273:808-812.
2. Brent GA, Larsen PR. Treatment of hypothyroidism. InBraverman LE, Utiger RD, eds. Wemer and Ingbar's The Thyroid; A Fundamental and Clinical Text. Philadelphia: Lippincott Williams & Wilkins; 2000:853-860.
3. Singer P, et al. Treatment guidelines for patients with thyroid nodules and well differentiated thyroid cancer. Arch Intern Med. 1996;156:2165-2172.
4. Dayan CM, Saravanan P, Bayly G. Whose normal thyroid function is better-yours or mine? Lancet. 2002;360:353-354.
5. Demers LM, Spencer CA. Laboratory medicine practice guidelines: Laboratory support for the diagnosis and monitoring of thyroid disease. Thyroid. 2003;13:2-104.
6. Hallowell JG, et al. Serun TSH, T4, and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab. 2002;87:489-499.
7. Vanderpump MPJ, et al. The incidence of thyroid disorders in the community: A twenty-year follow-up of the Whickham Survey. Clin Endocrinol. 1995;43:55-68.
8. Sawin CT, et al. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Engl J Med. 1994;331:1249-1252.
9. Parle JV, et al. Prediction of all-cause and cardiovascular mortality in elderly people from one low serum thyrotropin result: A 10-year cohort study. Lancet. 2001;358:861-865.
10. Anderson S, et al. Narrow individual variations in serum T4 and T3 in normal subjects: A clue to the understanding of subclinical thyroid disease. J Clin Endocrinol Metab. 2002;87:1068-1072.
11. Faber J, Galløe AM. Changes in bone mass during prolonged subclinical hyperthyroidism due to L-thyroxine treatment: A meta-analysis. Eur J Endocrinol. 1994;130:350-6.
12. Uzzan B, et al. Effects on Bone Mass of Long Term Treatment with Thyroid Hormones: A Meta-analysis. J Clin Endocrinol Metab. 1996;81:4278-4289.
13. Ching GW, et al. Cardiac hypertrophy as a result of long-term thyroxine therapy and thyrotoxicosis. Heart. 1996;75:363-368.
14. Biondi B, et al. Impaired cardiac reserve and exercise capacity in patients receiving long-term thyrotropin suppressive therapy with levothyroxine. J Clin Endocrinol Metab. 1996;81:4224-4228.
15. Foley TP. Congenital hypothyroidism, acquired hypothyroidism in infants, children and adolescents. In Braverman LE, Utiger RD, eds. Werner and Ingbar's The Thyroid: A Fundamental and Clinical Text, Philadelphia: Lippincott Williams & Wilkins; 2000;977-988.
16. Fisher DA. Thyroid disorders in childhood and adolescence: disorders of the thyroid in the newborn and infant. In Sperling MA, ed. Pediatric Endocrinology. Philadelphia: Saunders; 2002;161-209.
17. Mandel SJ, et al. Increased need for thyroxine during pregnancy in women with primary hypothyroidism. N Engl J Med. 1990;323:91-96.
18. Smallridge RC. Hypothyroidism in pregnancy. The Endocrinologist. 2002;12:454-464.
19. Haddow JE, et al. Maternal thyroid deficiency during pregnancy and subsequent neuropsychological development of the child. N Engl J Med. 1999;341:549-555.
20. Pop VJ, et al. Maternal Thyroid peroxidase antibodies during pregnancy: A marker of impaired child development. J Clin Endocrinol Metab. 1995;80:3561-3566.
21. Pop VJ, et al. Low maternal free thyroxine concentrations during early pregnancy are associated with impaired psychomotor development in infancy. Clinical Endocrinology. 1999;50:149-55.
22. Mazzaferri E. Carcinoma of follicular epithelium: Radioiodine and other treatment and outcomes. In Braverman LE, Utiger RD, eds. Werner and Ingbar's The Thyroid: A fundamental and clinical text. Philadelphia: Lippincott Williams and Wilkins; 2000;904-929.
23. Cobin RH, et al. AACE/AAES Medical/Surgical guidelines for clinical practice: Management of thyroid carcinoma. Endocrine Pract. 2001;7(3):203-220.
24. Association, B.T., Guidelines for the management of thyroid cancer in adults. British Thyroid Association: 2002. http://www.british-thyroid-association.org/guidelines.htm.
25. Sherman, S.I., et al., Clinical Practice Guidelines in Oncology: Thyroid Carcinoma. 2002, National Comprehensive Cancer Network: nccn.org. p. 1-69.
26. De Groot, L.J., Thyroid Algorithms: What is the correct thyroxine dosage? Endocrine Education Inc: Thyroid Disease Manager, 2003.
27. Pacini, F. and L.J. De Groot. The thyroid and its diseases: Thyroid cancer; 2003, Endocrine Education Inc.: Thyroid disease Manager.
28. Hung W. Thyroid disorders of infancy and childhood. In Becker KL, ed. Principles and Practice of Endocrinology and Metabolism: Philadelphia: Lippincott Williams & Wilkins; 2001;;462-471.
29. Bauer AJ, Tuttle RM, Francis GL. Differentiated thyroid carcinoma of children and adolescents. Endocrinologist. 2002;12:135-142.
30. Hennessey JV, Burman KD, Wartofsky L. The equivalency of two L-thyroxine preparations. Ann Intern Med. 1985;102:770-773.
31. Escalante DA, Arem N, Arem R. Assessment of interchangeability of Two Brands of Levothyroxine Preparations with a Third-Generation TSH Assay. Am J Med. 1995;98:374-378.
32. DeGroot LJ. Interchangeability of Levothyroxine Preparations (Correspondence). Am J Med. 1996;100:244-245.
33. Davies TF. Interchangeability of Levothyroxine Preparations (Correspondence). Am J Med. 1996;100:245-245.
34. Ridgway EC. Interchangeability of Levothyroxine Preparations (Correspondence). Am J Med. 1996;100:245-246.
35. Lyle BJ. Interchangeability of Levothyroxine Preparations (Correspondence). Am J Med. 1996;100:247-248.
36. Dong BJ, et al. Bioequivalence of Generic and Brand-name Levothyroxine Products in the Treatment of Hypothyroidism. JAMA. 1997;277:1205-1213.
37. Guidance for Industry: Bioavailability and Bioequivalence Studies for Orally Administered Drug Products-General Considerations, in U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Federal Drug Administration: www.fda.gov/cder/guidance/index.htm. 2002:1-24.
38. Mayor GH, Orlando T, Kurtz NM. Limitations of Levothyroxine Bioequivalence evaluation: Analysis of an Attempted Study. Am J Ther. 1995;2:417-432.
39. Wartofsky L. Bioequivalence of Levothyroxine Preparations: Shortcomings and Implications of a recently Published Study. Endocrinologist. 1997;7:322-333.
40. Docket Number 97N-0314, Prescription Drug Products; Levothyroxine Sodium. Fed. Register. 1997. 62: p. 43535-43538.
41. Conner D. Bioavailability (BA) and Bioequivalence (BE) of Endogenous Substance Drug Products. 2003, FDA: http://www.fda.gov/ohrms/dockets/ac/03/slides/3926S2_06_Conner.ppt.
42. Guidance for industry: Levothyroxine sodium tablets-In vivo pharmacokinetic and bioavailability studies and in vitro dissolution testing. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), 2000: p. 1-8.
43. Johnson, S. Endogenous Substance Bioavailability and Bioequivalence: Levothyroxine Sodium Tablets. 2003, FDA.
44. Granneman, G.R. Bioequivalence and baseline correction of endogenous substances. Case study: Levothyroxine sodium products in FDA advisory Committee for Pharmaceutical Science. 2003. Rockville, MD: Abbott Laboratories, Abbott Park, IL.
45. Electronic Orange Book, in US Parmacopeia. 2002, Federal Drug Administration: www.accessdata.fda.gov/scripts/cder.
46. Shield, B.C.a.B. 2003 Preferred Drug List. Providence, RI: Blue Cross and Blue Shield of Rhode Island; 2003.
47. Baskin HJ, et al. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Evaluation and Treatment of Hyperthyroidism and Hypothyroidism. Endocrine Pract. 2002;8:458-467.